Trends in Human Immunodeficiency Virus Infection among Drug Users in a Detoxification Unit
|
|
- Roy Preston
- 5 years ago
- Views:
Transcription
1 SUPPLEMENT ARTICLE Trends in Human Immunodeficiency Virus Infection among Drug Users in a Detoxification Unit Roberto Muga, Arantza Sanvisens, José Manuel Egea, Jordi Tor, and Celestino Rey-Joly Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain In a cross-sectional study of 1111 injection drug users (IDUs) admitted to a hospital detoxification unit between 1987 and 2001, characteristics of substance abuse and blood samples were obtained at study entry. The median age at admission was 27 years, the median age at first injection of drugs was 19 years, and the median duration of injection drug use was 84 months. Overall prevalence of human immunodeficiency virus (HIV) infection was 60% (58% in men, 66% in women; P p.026). Age at start of and duration of injection drug use were associated with HIV infection ( P!.001). The rate of HIV infection in persons with short duration of drug use (!24 months) was higher among women (45%) than among men (21%) ( P p.002). The prevalence of HIV infection among IDUs!21 years old at first use of injection drugs and among patients reporting!48 months of injection drug use was significantly lower in those who started injection drug use after 1992 (19% vs. 53% of IDUs; odds ratio, 4.42; 95% confidence interval, ). Awareness of acquired immunodeficiency syndrome, preventive measures, and substance abuse treatment have contributed to the stabilization of the HIV epidemic. The higher prevalence of HIV infection among women IDUs and among young IDUs who recently began injecting drugs emphasizes the need to target HIV-transmission risk reduction interventions early. Since 1981, a total of 61,028 people have received a diagnosis of AIDS in Spain [1]. In fact, the pairing of drug abuse and HIV infection is one of the most critical public health problems in our country because every 2 out of 3 AIDS cases are related to injection drug use. The sudden onset of the HIV epidemic coincided with the spread of injection heroin use in Spain in the late 1970s [2, 3]. The expansion of injection heroin use and the lack of knowledge of the modes of HIV transmission was of fundamental importance to the spread of HIV at the beginning of the 1980s; by 1993, Spain had the highest cumulative incidence of AIDS cases in Western Europe. Grant support: Fondo de Investigación Sanitaria (FIS), Ministry of Health, Spain (FIS 00/0294, FIS G03/005). Reprints or correspondence: Dr. Roberto Muga, Dept. of Internal Medicine, Rm. 806, Hospital Universitari Germans Trias i Pujol, Carretera Canyet s/n, Badalona, Barcelona, Spain (rmuga@ns.hugtip.scs.es). Clinical Infectious Diseases 2003; 37(Suppl 5):S by the Infectious Diseases Society of America. All rights reserved /2003/3712S5-0014$15.00 Previous studies have demonstrated that 2 groups, injection drug users (IDUs) who start injection drug use at an early age and women, are at increased risk of HIV infection, even in areas where extensive prevention and harm reduction programs have been implemented [4 9]. From a public health perspective, the monitoring of the prevalence of HIV infection and the identification of target groups of young IDUs who recently started injecting drugs are essential for the development of effective health interventions [10]. In our setting, the scarcity of prospective studies on the incidence of HIV infection reinforces the need to analyze the temporal trends of prevalence. Furthermore, the decrease in the number of cases of AIDS in Spain since 1997 may be attributed not just to the introduction of HAART but also to a lower rate of infection among IDUs, because injection drug use is the main route of HIV transmission. The objective of this study was to monitor trends in the prevalence of HIV infection in a hospital detoxification unit where IDUs with the most severe patterns of drug use were referred over the last 15 years. S404 CID 2003:37 (Suppl 5) Muga et al.
2 PATIENTS, MATERIALS, AND METHODS Study design and study population. This was a cross-sectional study of IDUs admitted to a 4-bed detoxification unit in a tertiary hospital in Badalona (metropolitan Barcelona) between February 1987 and December Patients were referred from outpatient clinics for substance abuse treatment. Further details regarding the criteria for admission and the characteristics of detoxification treatment have been published elsewhere [11]. Briefly, the majority of subjects included in this study were heroin users who injected the drug an average of 3 times a day and showed clear criteria of heroin dependence. At admission, subjects provided blood samples for determination of HIV (confirmed by EIA and Western blot), hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), and syphilis (confirmed by rapid plasma reagin [RPR] and microhemagglutination [MHA-TP] tests) and completed an interviewer-administered (face-to-face) questionnaire regarding demographic and drug use characteristics. Date of and age at first injection of drugs and duration of injection drug use were specifically asked for during the interview. For the purpose of this study, patients who were admitted to the detoxification unit 11 time between 1987 and 2001 were assessed only at their first admission. Statistical analysis. Data analysis was done with Student s t test or analysis of variance and the x 2 test. The magnitude of the univariate associations for HIV infection and variable predictors were measured by odds ratios with 95% confidence intervals. P!.05 was considered statistically significant. Statistical analysis was done with SPSS version 11.5 (SPSS) and Epi Info version 6 (Centers for Disease Control) packages. RESULTS Table 1. Characteristics of 1111 injection drug users at admission to a hospital detoxification unit, February 1987 to December Characteristic Value Sex Male 903/1111 (81) Female 208/1111 (19) Injection drug use a Age at start, median years 19 Date of start, median May 1985 Duration, median months 84 Age at hospital admission, median years 27 Infection status HIV positive 661/1111 (60) HCV positive b 325/354 (92) HBsAg positive 77/973 (8) Positive for syphilis 23/691 (3) NOTE. Data are no. of patients with characteristic/no. tested (%), unless indicated otherwise. HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus. a Data for 1104 patients. b Testing for HCV antibodies was done after September From February 1987 through December 2001, 1144 IDUs were admitted to the detoxification unit. Thirty-three patients (2.9%) did not provide a blood sample to test for HIV, so the population of the study was 1111 patients. Of these, 39% of patients had been incarcerated before admission. Seventy-nine percent of patients reported a temporary cessation of injection drug use (median duration of cessation, 14 months; interquartile range [IQR], 6 34 months). For 7 of the 1111 cases, we do not have information regarding age at and date of first injection of drugs and duration of injection drug use. Thirty-four percent of patients began injection drug use at age!18, 35% between the ages of 18 and 21, and 31% at age 21. The duration of injection drug use before admission was!24 months for 16% of the patients, months for 16%, and 148 months for 68%. Table 1 shows the characteristics of the patient population at entry: 81% of patients were men, the median age at admission was 27 years (IQR, years), and the median duration of injection drug use was 84 months (IQR, months). Globally, 60% of patients were HIV-positive, 92% were HCV-positive, 8% were HBsAg-positive, and 3% had positive results of RPR and MHA-TP testing. HIV-positive IDUs had started injection drug use earlier (mean, January 1984) than had those who were HIV-negative (mean, June 1988). The proportion of women was higher among HIV-positive subjects than among those who were HIVnegative (21% vs. 16% of patients; P p.03). Patients age at the start of injection drug use was younger among HIV-positive IDUs than among HIV-negative IDUs (mean ages, vs years; P!.001). Also, the duration of injection drug use was significantly longer among HIV-positive IDUs than among those who were HIV-negative (mean duration, vs months; P!.001). The prevalences of HCV infection and of positive serologic test results for syphilis (as determined by RPR and MHA-TP tests) were significantly higher in HIV-positive IDUs (98% and 4% of patients, respectively) than in HIV-seronegative IDUs (86% and 2%) ( P!.001). Prevalence of HBsAg positivity was similar in HIV-positive (8% of patients) and HIV-negative (7%) IDUs ( P p.47). As determined by use of similar recruitment strategies and interviewer-administered questionnaires, the characteristics of patients have changed over the last 15 years. Age at the start of injection drug use, duration of injection drug use, and age at admission have significantly increased for those admitted between 1997 and 2001 (table 2). However, the proportion of male IDUs remained stable and the prevalence of HIV de- HIV Infection Trends among IDUs CID 2003:37 (Suppl 5) S405
3 Table 2. Characteristics of 1111 injection drug users at admission to a hospital detoxification unit, by calendar periods of admission, February 1987 to December Period of admission Characteristic (n p 491) (n p 390) (n p 230) Male, % of patients Date of birth, mean May 1963 Jan 1966 Jan 1968!.001 Injection drug use Age at start, mean years !.001 Duration, mean months !.001 Age at admission, mean years !.001 Infection status, % of patients HIV positive !.001 HCV positive NA 93 b HBsAg positive Positive for syphilis NOTE. HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; NA, not available. a P for comparison of calendar periods of admission. b Testing for HCV antibodies was performed after September creased from 70% to 48%, despite the fact that the patients admitted between 1997 and 2001 had a longer duration of injection drug use. In relation to year of first injection of drugs, 61.4% of subjects (678 of 1104 patients) started using injection drugs before 1987, whereas 13.7% (151 of 1104) started after Table 3 shows the association of HIV-infection prevalence with calendar periods of start of injection drug use (!1987, , 11992), sex, and age at first injection of drugs. Despite a significant decrease in the prevalence of HIV infection in the period later than 1992, 25% of those IDUs who started injection drug use before the age of 18 and 35% of the women with short duration of injection drug use were HIV positive. Table 3. Prevalence of HIV infection among 1111 injection drug users at admission to a hospital detoxification unit in 3 calendar periods, according to sex and to age at the start of injection drug use. Characteristic No. (%) of patients positive for HIV, by period injection drug use started Before 1987 (n p 678) Figures 1 3 show the downward trend in HIV-infection prevalence with regard to the year of starting injection drug use, sex, and age at first injection drug use in persons with comparable durations of injection. Patients starting injection drug use after 1992, men, and persons 121 years old when they started using injection drugs show less prevalence of HIV infection than do those starting before 1992, females, and IDUs!18 years old when they began using injection drugs. Table 4 shows the odds of being HIV positive according to sex and age at start of injection drug use, after controlling for the duration ( 48 months or 148 months) and the calendar period (1992 and before, or after 1992) of injection drug use. IDUs who reported 14 years of injection drug use and first parenteral use of (n p 275) After 1992 (n p 151) Sex Male 402 (74) 96 (42) 22 (18)!.001 Female 100 (76) 27 (56) 9 (35)!.001 Age at start of injection drug use, years! (76) 36 (54) 4 (25)! (77) 44 (43) 9 (27)! (64) 43 (40) 18 (18)!.001 P a P a a P for comparison of periods of starting injection drugs. S406 CID 2003:37 (Suppl 5) Muga et al.
4 Figure 1. Prevalence of HIV (% of patients infected) according to calendar periods of start of injection drug use and duration of injection drug use. (*), P for comparison of HIV-infection prevalence by period of starting injection drug use within same category of duration (i.e., for those reporting 14 years of injection drug use, prevalence of HIV was 76% if they started injecting before 1987, 49% if they started between 1987 and 1992, and 33% if they started after 1992; P p.003). (**), P for comparison of HIV-infection prevalence by period of starting injection drug use according to 3 categories of duration of injection drug use (i.e., prevalences of HIV in those starting injection drug use before 1987 and reporting 14 years, 2 4 years, or!2 years of injection drug use were 76%, 60%, and 48%, respectively; P p.001). drugs before 1992 had an increased probability of being HIVpositive than did those with similar characteristics who started injecting drugs after 1992 (OR, 5.39; 95% CI, ). DISCUSSION During 15 years, we have monitored the prevalence of HIV in hard-line IDUs, which has allowed us to confirm the stabilization of the epidemic regarding the main category of transmission in Spain. In this respect, the decrease in the number of cases of AIDS in Spain since 1997 may have not been due merely to the effectiveness of HAART but also to the reduction in the number of new HIV-infected IDUs. Recently, the European Monitoring Centre for Drugs and Drug Addiction (Lisbon) has reported similar trends in HIV infection among Span- Figure 2. Prevalence of HIV (% of patients infected) according to sex and duration of injection drug use. (*), P for comparison of HIV-infection prevalence in men and women within same category of duration (i.e., for those reporting 14 years of injection drug use, prevalence of HIV was 76% in women vs. 69% in men; P p.095). (**), P for comparison of HIV-infection prevalence by sex according to 3 categories of duration of injection drug use (i.e., prevalences of HIV in women reporting 14 years, 2 4 years, or!2 years of injection drug use were 76%, 53%, and 45%, respectively; P p.001). HIV Infection Trends among IDUs CID 2003:37 (Suppl 5) S407
5 Figure 3. Prevalence of HIV (% of patients infected) according to age at start of injection drug use and duration of injection drug use. (*), P for comparison of HIV-infection prevalence by age at starting injection within same category of duration (i.e., for those reporting 14 years of injection drug use, prevalence of HIV was 74% if they started injection at age!18 years, 71% if they started at age years, and 61% if they started at age 121 years; P p.026). (**), P for comparison of HIV-infection prevalence by age at starting injection according to 3 categories of duration (i.e., prevalences of HIV in those starting injection at age!18 years and reporting 14 years, 2 4 years, or!2 years of injection drug use were 74%, 54%, and 41%, respectively; P p.001). Table 4. ORs for HIV infection in a cohort of 1111 injection drug users according to sex and age at start of injection drug use. Characteristic, period injection drug use started ish drug users [12]. If the findings of this study regarding the prevalence of HIV relate to heavy users of injection drugs, it is probable that persons with less-severe patterns of drug abuse will show a similar reduction. Of note, the decrease in the prevalence of HIV infection is not observed in other common bloodborne infections, such as HCV, or in the percentage of chronic carriers of HBsAg. We found a consistent and gradual downward trend in HIVinfection prevalence in IDUs who began injection drug use after 1992, regardless of the age at first injection drug use and of sex, and in persons with comparable durations of injection drug use. In that year, programs of methadone substitution treatment for heroin dependence started to be generalized in the city of Barcelona, and that intervention has been one of the major initiatives in diminishing the spread of HIV [13, 14]. Despite the decrease in the prevalence of HIV infection, we OR (95% CI) for HIV infection, by duration of injection drug use 48 months 148 months Age at start of injection drug use 21 years Before or during ( ) 4.14 ( ) 121 years Before or during ( ) 5.39 ( ) Sex Male Before or during ( ) 2.29 ( ) Female Before or during ( ) 2.73 ( ) S408 CID 2003:37 (Suppl 5) Muga et al.
6 identified 2 subsets of persons who deserve special attention because they maintain a relatively high prevalence of HIV: women and those IDUs who started injection at a young age. During the first 2 years of injection drug use, women have more than twice the prevalence of HIV infection that male IDUs have, and these differences were similar before and after The explanation for the excess of infection has been related to the high frequency of exchanging drugs for sex [15, 16] and/or of having a sex partner who is also an IDU [17]. Concerning the age of starting drug use, those who start at a younger age always show a higher prevalence of HIV. Young age is associated with high-risk behavior related to drug use, and in this regard, to delay the age of starting drug use can be favorable to the acquisition of habits that prevent the transmission of bloodborne infections [18 20]. Several limitations should be noted in this study. The external validity and generalization of results can be limited when only a single treatment center is taken into account to analyze the evolution of the HIV epidemic. In this hospital cohort, a bias in survival is possible because of the fact that IDUs could die from AIDS or overdose before admission. Last, some patients cannot assess the date when they started injection drug use, in particular those IDUs with chronic, long-term addiction. However, the recall bias is not usually observed among those who have injected drugs for only a few years. From this study, we can infer the necessity for implementing preventive interventions for female IDUs and for those young and recent initiates. Early diagnosis of the addiction, promoting harm reduction in HIV prevention, and treatment for drug abuse are effective ways to curtail the spread of HIV infection. References 1. Vigilancia epidemiológica del VIH/sida en España. Actualización a 30 de junio de Parte I. Publicacion Oficial de Seisida 2002; 13: Barrio G, de la Fuente L, Cami J. The consumption of drugs in Spain and its position in European context [in Spanish]. Med Clin (Barc) 1993; 101: Gamella JF. The spread of intravenous drug use and AIDS in a neighborhood in Spain. Med Anthropol Q 1994; 8: Egea JM, Tor J, Muga R, et al. Rates of human immunodeficiency virus (HIV) infection in intravenous drug addicts from the Barcelona area, according to sex and age of drug consumption onset [in Spanish]. Med Clin (Barc) 1996; 106: Solomon L, Astemborski J, Warren D, et al. Differences in risk factors for human immunodeficiency virus type 1 seroconversion among male and female intravenous drug users. Am J Epidemiol 1993; 137: Freeman RC, Rodriguez GM, French JF. A comparison of male and female intravenous drug users risk behaviors for HIV infection. Am J Drug Alcohol Abuse 1994; 20: Battjes RJ, Leukefeld CG, Pickens RW. Age at first injection and HIV risk among intravenous drug users. Am J Drug Alcohol Abuse 1992; 18: Sabbatini A, Carulli B, Villa M, et al. Recent trends in the HIV epidemic among injecting drug users in Northern Italy, AIDS 2001; 15: Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: van Ameijden EJC, Coutinho RA. Maximum impact of HIV prevention measures targeted at injecting drug users. AIDS 1998; 12: Muga R, Roca J, Egea JM, et al. Mortality of HIV-positive and HIVnegative heroin abusers as a function of duration of injecting drug use. J Acquir Immune Defic Syndr 2000; 23: European Monitoring Centre for Drugs and Drug Addiction. Annual report on the state of the drug problem in the European Union and Norway. Luxembourg: Office for Official Publications of European Communities, Available at: Accessed October Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among drug users in and out of treatment: an 18 month prospective follow-up. J Acquir Immune Defic Syndr 1993;6: Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep 1998; 113(Suppl 1): Solomon L, Astemborski J, Warren D, et al. Differences in risk factors for human immunodeficiency virus type 1 seroconversion among male and female intravenous drug users. Am J Epidemiol 1993; 137: Astemborski J, Vlahov D, Warren D, Solomon L, Nelson KE. The trading of sex for drugs or money and HIV seropositivity among female intravenous drug users. Am J Public Health 1994; 84: Barnard MA. Needle sharing in context; patterns of sharing among men and women injectors and HIV risks. Addiction 1993; 88: Battjes RJ, Leukefeld CG, Pickens RW. Age at first injection and HIV risk among intravenous drug users. Am J Drug Alcohol Abuse 1992; 18: Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS 2000; 14: Miller CL, Tyndall M, Spittal P, Li K, LaLiberte N, Schechter MT. HIV incidence and associated risk factors among young injection drug users. AIDS 2002; 16: HIV Infection Trends among IDUs CID 2003:37 (Suppl 5) S409
Mortality rates among injection drug users (IDUs) have been historically high and are still significantly higher
HIV/AIDS MAJOR ARTICLE Survival of HIV-Infected Injection Drug Users (IDUs) in the Highly Active Antiretroviral Therapy Era, Relative to Sex- and Age-Specific Survival of HIV-Uninfected IDUs Roberto Muga,
More informationORIGINAL INVESTIGATION. Sex Differences in Risk Factors for HIV Seroconversion Among Injection Drug Users
Sex Differences in Risk Factors for HIV Seroconversion Among Injection Drug Users A 10-Year Perspective ORIGINAL INVESTIGATION Steffanie A. Strathdee, PhD; Noya Galai, PhD; Mahboobeh Safaiean, MPH; David
More informationDHMH Activities toward Implementing Requirements of Md. Code Ann., Health-General , Hepatitis C Prevention and Control within Maryland
DHMH Activities toward Implementing Requirements of Md. Code Ann., Health-General 18-1001, Hepatitis C Prevention and Control within Maryland Submitted by: Maryland Department of Health and Mental Hygiene
More informationHarm reduction among drug users in Spain
Harm reduction among drug users in Spain Luxemburg,, 27 October 21 Dr. José Manuel Arroyo Cobo Deputy Director General of Health in Prisons Ministry of Internal Affairs Dr. Tomás s Hernández ndez Fernández
More informationNarrative Science-based literature on Syringe Exchange Programs (SEPs)
Narrative Science-based literature on Syringe Exchange Programs (SEPs) 1996 2007 Background: In 1988, the US Department of Health and Human Services (HHS) prohibited the use of federal money to be used
More informationBackground. Population/Intervention(s)/ Comparison/Outcome(s) (PICO)
updated 2012 Role of sterile injection equipment and outreach programmes for injecting drug users Q 6. Does the provision of sterile injection equipment to injecting drug users reduce injecting related
More informationIn-class exercise on Selection Bias Instructor Guide
In-class exercise on Selection Bias Instructor Guide Background The HIV epidemic in the United States began in the 1980's through three major sources of transmission: anal sexual intercourse, viral contamination
More informationSources of Error. Background
Background Sources of Error The HIV epidemic in the United States began in the 1980's through three major sources of transmission: anal sexual intercourse, viral contamination of blood and blood products,
More informationFactors Associated with Syringe Sharing Among Users of a Medically Supervised Safer Injecting Facility
American Journal of Infectious Diseases 1 (1): 50-54, 2005 ISSN 1553-6203 2005 Science Publications Factors Associated with Syringe Sharing Among Users of a Medically Supervised Safer Injecting Facility
More informationNeedle exchange programs
Needle exchange programs What science tells us about needle exchange programs Kerstin Käll, MD, PhD University of Linköping, Sweden Klas Rönnbäck, Ulrich Hermansson, Sten Rönnberg HIV and Injecting Drug
More informationHepatitis C Incidence a Comparison Between Injection and Noninjection Drug Users in New York City
Journal of Urban Health: Bulletin of the New York Academy of Medicine Vol. 81, No. 1, March 2004 2004 The New York Academy of Medicine Hepatitis C Incidence a Comparison Between Injection and Noninjection
More informationLiver Enzyme Alterations in HCV-Monoinfected and HCV/HIV-Coinfected Patients
82 The Open AIDS Journal, 2008, 2, 82-88 Open Access Liver Enzyme Alterations in HCV-Monoinfected and HCV/HIV-Coinfected Patients Klaus Langohr 1,2, Arantza Sanvisens 1, Daniel Fuster 1, Jordi Tor 1, Isabel
More informationPREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS
PREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS Holly Hagan, PhD Professor Co-Director, Center for Drug Use and HIV Research Principal Investigator, HCV Synthesis Project New York University HCV prevalence
More informationINTRAVENOUS INJECTING DRUG USE.
Injecting drug users in Europe Towards an educational approach Lucas Wiessing European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon lucas.wiessing@ emcdda.org www.emcdda.org It has been
More informationInjection Drug Users: The Prevalence
Viral Infections in Short-Term Injection Drug Users: The Prevalence of the Hepatitis C, Hepatitis B, Human Immunodeficiency, and Human T-Lymphotropic Viruses Richard S. Garfein, MPH, David Vlahov, PhD,
More informationRapid transmission of hepatitis C virus among young injecting heroin users in Southern China
IJE vol.33 no.1 International Epidemiological Association 2004; all rights reserved. International Journal of Epidemiology 2004;33:182 188 DOI: 10.1093/ije/dyh019 Rapid transmission of hepatitis C virus
More informationPrevalence and correlates of hepatitis C infection among users of North America s first medically supervised safer injection facility
Public Health (2005) 119, 1111 1115 Prevalence and correlates of hepatitis C infection among users of North America s first medically supervised safer injection facility E. Wood a,b, *, T. Kerr a, J. Stoltz
More informationUpdating the Infection Risk Reduction Hierarchy: Preventing Transition into Injection
Journal of Urban Health: Bulletin of the New York Academy of Medicine Vol. 81, No. 1, March 2004 2004 The New York Academy of Medicine SPECIAL FEATURE: HEPATITIS C VIRUS Updating the Infection Risk Reduction
More informationHIV Risk Behaviour in Irish Intravenous Drug Users
Abstract HIV Risk Behaviour in Irish Intravenous Drug Users A. Dorman, E. Keenan, C. Schuttler, J. Merry, J. J. O Connor The Drug Treatment Centre Board, Trinity Court, 30/31 Pearse Street, Dublin 2. The
More informationChiang Mai University/Johns Hopkins University HIV/AIDS Research on VCT
Chiang Mai University/Johns Hopkins University HIV/AIDS Research on VCT David Celentano, Professor of Epidemiology May 26, 2005 Scope of the CMU/JHU Collaborative HIV/AIDS Research Agenda HIV/AIDS research
More informationSyringe Exchange Research Update Harm Reduction Coalition August 2008
Syringe Exchange Research Update August 2008 Introduction This overview and annotated bibliography summarizes key recent research on syringe exchange programs in the United States and related data on injection
More informationEpidemiology of Hepatitis C Iran
Seyed Moayed Alavian M.D. Professor of Gastro & Hepatology Editor-in-chief of Glob Hepat Comm Editor-in-chief of Hepatitis Monthly E mail: editor@hepatmon.com Epidemiology of Hepatitis C Iran Epidemiology
More informationChanges in injecting practices associated with the use of a medically supervised safer injection facility
Journal of Public Health Vol. 29, No. 1, pp. 35 39 doi:10.1093/pubmed/fdl090 Advance Access Publication 17 January 2007 Changes in injecting practices associated with the use of a medically supervised
More informationTrends in injecting drug use in Europe
Trends in injecting drug use in Europe Linda Montanari, Bruno Guarita and Danica Thanki Annual Expert Meeting on Drug-Related Infectious Diseases Lisbon, 15-17 October Overview of the presentation 1) Information
More informationSyringe Exchange Programs December 2005
Syringe Exchange Programs December 2005 In 1997, a Report to Congress concluded that needle exchange programs can be an effective component of a comprehensive strategy to prevent HIV and other blood-borne
More informationMortality in an Urban Cohort of HIV-Infected and At-Risk Drug Users in the Era of Highly Active Antiretroviral Therapy
HIV/AIDS MAJOR ARTICLE Mortality in an Urban Cohort of HIV-Infected and At-Risk Drug Users in the Era of Highly Active Antiretroviral Therapy Rakhi Kohli, 1,a Yungtai Lo, 2 Andrea A. Howard, 1,2 Donna
More informationChin-Hui Yang, M.D. Hui-Rong Liu, Sung-Yin Chen, Yen-Fang Huang, Shih-Yan Yang Third Division, Centers for Disease Control, Department of Health,
Comparison of ff Factors affecting the mortality rate of Injecting Drug Users with HIV infection in Taiwan Chin-Hui Yang, M.D. Hui-Rong Liu, Sung-Yin Chen, Yen-Fang Huang, Shih-Yan Yang Third Division,
More informationSouth Asian Cocktail The Predominant Drug Use Pattern in Nepal and its Association with Spread of HIV
14 Original Article South Asian Cocktail The Predominant Drug Use Pattern in Nepal and its Association with Spread of HIV Ojha S P 1, Sigdel S 2, H-G M 3, Verthein U 4 1 Tribhuvan University Teaching Hospital,
More informationThirty years of harm reduction in the Netherlands HCV elimination ahead?
Thirty years of harm reduction in the Netherlands HCV elimination ahead? Esther Croes, MD PhD Confession 30 years 3 topics: drug use, harm reduction, HCV in 15 minutes IT DOESN T FIT!! 2 Disclosure Esther
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationIntravenous drug use is currently the main transmission
A Prospective Controlled Study of Interferon-Based Therapy of Chronic Hepatitis C in Patients on Methadone Maintenance Stefan Mauss, 1 Florian Berger, 1 Joerg Goelz, 2 Bernhard Jacob, 3 and Günther Schmutz
More informationPrevalence of HIV and risk behaviors among injecting drug users in Tallinn, Estonia in a series of cross-sectional studies
Prevalence of HIV and risk behaviors among injecting drug users in Tallinn, Estonia in a series of cross-sectional studies Sigrid Vorobjov 1, Maris Salekešin 1, Katri Abel-Ollo 1, Anneli Uusküla 2, Don
More informationPoland nationalupdate
Poland nationalupdate 16th October 2014 Annual expert meeting on Drug-related deaths (DRD) and Drug-related infectious diseases (DRID) Estimation of HIV and HCV prevalence among injecting drug users in
More informationPrevalence and Correlates of Hepatitis C Virus Infection among Street-Recruited Injection Drug Users in San Juan, Puerto Rico
Journal of Urban Health: Bulletin of the New York Academy of Medicine doi:10.1007/s11524-006-9109-7 * 2006 The New York Academy of Medicine Prevalence and Correlates of Hepatitis C Virus Infection among
More informationInjection Drug Use in the United States
Injection Drug Use in the United States M. Fe Caces Office of National Drug Control Policy Executive Office of the President Washington, DC 20503 Presentation at the Treatment Demand Indicators Expert
More informationHepatitis C Virus Infection: Prevalence, Risk Factors, and Prevention Opportunities among Young Injection Drug Users in Chicago,
1588 Hepatitis C Virus Infection: Prevalence, Risk Factors, and Prevention Opportunities among Young Injection Drug Users in Chicago, 1997 1999 Lorna E. Thorpe, 1,a Lawrence J. Ouellet, 1 Jennie R. Levy,
More informationclinic in Israel: disease incidence
15 years of Methadone Maintenance Treatment clinic in Israel: Drug abuse abstinence and minimal infectious disease incidence Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse Treatment & Research Tel-Aviv
More informationMortality Among Young Injection Drug Users in San Francisco: A 10-Year Follow-up of the UFO Study
American Journal of Epidemiology ª The Author 2012. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail:
More informationPublic drug policies Catalonia
Public drug policies Catalonia Public Health Agency of Catalonia Xavier Majó Roca Catalonia Barcelona Territory: 32.000 km2 Population: 7.523.000 M Own language and culture 1. What s happened in Catalonia
More informationHIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications
HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications Don Des Jarlais, Ph.D. Professor of Psychiatry, Icahn School of Medicine at Mount Sinai UNODC 2014
More informationDifferences in Prevalence of Prescription Opiate Misuse Among Rural and Urban Probationers
The American Journal of Drug and Alcohol Abuse, 33: 309 317, 2007 Copyright Q Informa Healthcare ISSN: 0095-2990 print/1097-9891 online DOI: 10.1080/00952990601175078 Differences in Prevalence of Prescription
More informationKAZAKHSTAN. National Focal Point. Drug Abuse and Drug Dependence Treatment Situation. Territory : 2,717,300 km 2 Capital: Astana BASIC DATA
KAZAKHSTAN Territory : 2,717,300 km 2 Capital: Astana Map No. 3771 Rev. 6 UNITED NATIONS January 2004 BASIC DATA Total population (millions) 2009 15.5* Population under age15 (as % of total) 2010 23.8*
More informationNew Brunswick Report on Sexually Transmitted and Blood Borne Infections, 2016
New Brunswick Report on Sexually Transmitted and Blood Borne Infections, 6 Table of Contents. Introduction.... Methodology... 3. Data Limitations.... Definitions used... 3 5. Overview of STBBI epidemiology
More informationAppendix 1: Supplementary tables [posted as supplied by author]
Appendix 1: Supplementary tables [posted as supplied by author] Table A. Medline search strategies used to identify relevant articles Search 1 a Search 2 1 *HIV infections/pc (MESH) 2 (HIV or human immunodeficiency
More informationDo Supervised Injecting Facilities Attract Higher-Risk Injection Drug Users?
Brief Reports Do Supervised Injecting Facilities Attract Higher-Risk Injection Drug Users? Evan Wood, PhD, Mark W. Tyndall, MD, ScD, Kathy Li, MSc, Elisa Lloyd-Smith, BSc, Will Small, MA, Julio S.G. Montaner,
More informationThe Emergence of Gabapentin as a Drug of Abuse in a Cohort of Rural Appalachian Drug Users
The Emergence of Gabapentin as a Drug of Abuse in a Cohort of Rural Appalachian Drug Users Jennifer R. Havens, PhD, MPH Center on Drug and Alcohol Research Goals Describe the epidemiology of gabapentin
More information5/2/2016. Dr Brooks has no relevant financial affiliations to disclose. (Update 04/15/16) Learning Objectives
Persistent Challenge of HIV Transmission Control in Injection Drug Use: The Indiana Outbreak John T. Brooks, MD Senior Medical Advisor, Division of HIV/AIDS Prevention National Center for HIV/AIDS, Viral
More informationUniversity of Groningen
University of Groningen Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus van den Berg, Charlotte; Smit, Colette;
More informationEvidence-based findings on the efficacy of syringe exchange programs: an analysis of the scientific research completed since April 1998
U.S. Department of Health and Human Services Washington, DC March 17, 2000 Evidence-based findings on the efficacy of syringe exchange programs: an analysis of the scientific research completed since April
More informationStudy of Hepatitis B Virus and Hepatitis C Virus Co-infection in Human Immunodeficiency Virus Seropositive Cases Jose P. Augustine
Study of Hepatitis B Virus and Hepatitis C Virus Co-infection in Human Immunodeficiency Virus Seropositive Cases Jose P. Augustine Assistant Professor, Department of Microbiology, Sree narayana Institute
More informationTrends in HIV/AIDS epidemic in Asia, and its challenge. Taro Yamamoto Institute of Tropical Medicine Nagasaki University
Trends in HIV/AIDS epidemic in Asia, and its challenge Taro Yamamoto Institute of Tropical Medicine Nagasaki University Millennium Development Goals Goal 1. Eradicate extreme poverty and hunger Goal 2.
More informationHigh prevalence and incidence of HIV and HCV among new injecting drug users with a large proportion of migrants Is prevention failing?
High prevalence and incidence of HIV and HCV among new injecting drug users with a large proportion of migrants Is prevention failing? Cinta Folch on behalf of REDAN Study Group Viral Hepatitis Prevention
More informationEpidemiology of hepatitis E infection in Hong Kong
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Epidemiology of hepatitis E infection in Hong Kong DPC Chan *, KCK Lee, SS Lee K e y M e s s a g e s 1. The overall anti hepatitis E virus (HEV) seropositivity
More informationModels of good practice in drug treatment in Europe. Project group
Models of good practice in drug treatment in Europe ( moretreat 2006329 ) Project group Hamburg, London, Rome, Stockholm, Vienna, Warsaw, Zurich Project duration: 17 months from April 2006 August 2008
More informationRisky sexual behaviours among injection drugs users with high HIV prevalence: implications for STD control
i170 SYMPOSIUM Risky sexual behaviours among injection drugs users with high HIV prevalence: implications for STD control M W Tyndall, D Patrick, P Spittal, K Li, M V O Shaughnessy, M T Schechter... Injection
More informationOverview of Evidence for Sterile Syringe Access. Hilary McQuie Western Director Harm Reduction Coalition
Overview of Evidence for Sterile Syringe Access Hilary McQuie Western Director Harm Reduction Coalition Working Definition of Harm Reduction Harm Reduction: A set of practical, public health strategies
More informationAlabama s Emerging Hepatitis C Epidemic and Vulnerability to an Outbreak of HIV Infection Among Persons Who Inject Drugs
Alabama s Emerging Hepatitis C Epidemic and Vulnerability to an Outbreak of HIV Infection Among Persons Who Inject Drugs James W. Galbraith MD Associate Professor Department of Emergency Medicine UAB Medicine
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationAs a result of this training, participants will be able to:
Addressing Prevention with HIV Positive Clients 1 Day Training This one-day training will prepare participants to help people living with HIV to avoid sexual and substance use behaviors that can result
More informationState of Alabama HIV Surveillance 2013 Annual Report Finalized
State of Alabama HIV Surveillance 2013 Annual Report Finalized Prepared by: Division of STD Prevention and Control HIV Surveillance Branch Contact Person: Allison R. Smith, MPH Allison.Smith@adph.state.al.us
More informationHIV in Prison Situation in Frankfurt am Main
HIV in Prison Situation in Frankfurt am Main European Project ROME-SEMINAR, May 14.-15., 2008 Horst Herkommer, Sella Oneko Praxis Psychosoziale Beratung Frankfurt am Main Germany General remark: Situation
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More informationBy: Randolph F.R. Rasch, Christopher A. Weisen, Bruce MacDonald, Wendee M. Wechsberg, Rebecca Perritt, and Michael L. Dennis
Patterns of HIV risk and alcohol use among African-American crack abusers By: Randolph F.R. Rasch, Christopher A. Weisen, Bruce MacDonald, Wendee M. Wechsberg, Rebecca Perritt, and Michael L. Dennis Rasch,
More informationEMCDDA-update HIV/HCV among people who inject drugs: situation and response
EMCDDA-update HIV/HCV among people who inject drugs: situation and response Dagmar Hedrich EU Think Tank HIV/AIDS: 24-25 November 2015, Luxembourg Latest European overview Multi-indicator based analysis
More informationMarkers of Inflammation and Mortality in a Cohort of Patients With Alcohol Dependence
Markers of Inflammation and Mortality in a Cohort of Patients With Alcohol Dependence Daniel Fuster, Arantza Sanvisens, Ferran Bolao, Paola Zuluaga, Inmaculada Rivas, Jordi Tor, and Robert Muga Abstract:
More informationEvaluation of the Coris Legionella V-Test. In comparison with the Trinity Biotech EIA Legionella Urinary Antigen test
Evaluation of the Coris Legionella V-Test In comparison with the Trinity Biotech EIA Legionella Urinary Antigen test 06/September/2010 Coris BioConcept Report of Clinical Performance Study of Legionella
More informationStable incidence of hepatitis C virus infection among PWID in an Australian prison setting, : the HITS-p study
Stable incidence of hepatitis C virus infection among PWID in an Australian prison setting, 2005-2014: the HITS-p study Evan B. Cunningham 1, Brigid Betz-Stablein 2, Neil A. Bretana 2, Gregory J. Dore
More informationHeroin Use in Illinois: A Ten-Year Multiple Indicator Analysis, 1998 to 2008
Heroin Use in Illinois: A Ten-Year Multiple Indicator Analysis, 1998 to 2008 EXECUTIVE SUMMARY AND FINDINGS Co-authored by: Stephanie Schmitz Kathleen Kane-Willis Research Support: Laura Reichel, Elizabeth
More informationUNAIDS 99.1E (English original, March 1999) This document, presenting a speech given at the United Nations General Assembly Special Session on Drugs,
U N A I D S B E S T P R A C T I C E C O L L E C T I O N Drug use and HIV/AIDS UNAIDS statement presented at the United Nations General Assembly Special Session on Drugs Joint United Nations Programme on
More informationHarm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD
Harm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD Objectives Provide an overview of harm reduction by defining shared language and key terms. Collaboratively
More informationA Study of Seroprevalence of Hepatitis B, Hepatitis C and Syphilis Coinfection among HIV Patients in a Tertiary Care Teaching Hospital, South India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 8 (2016) pp. 698-707 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.508.079
More informationU.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs
U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs Michelle Van Handel, MPH Health Scientist National Center for HIV/AIDS, Viral Hepatitis, STDs and
More informationAcute hepatitis C The European Experience
Acute hepatitis C The European Experience Dr Emma Page MBBS MRCP MD(Res) Chelsea and Westminster Hospital, London AHC the European Experience 1. Epidemic 2. CNS sequelae 3. Incidence 4. Re-infection Reports
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationGender differences in sexual behaviors, sexual partnerships, and HIV among drug users in New York City
AIDS Behav (2006) 10:707 715 DOI 10.1007/s10461-006-9082-x ORIGINAL PAPER Gender differences in sexual behaviors, sexual partnerships, and HIV among drug users in New York City Judith Absalon Crystal M.
More informationPractice Steps for Implementation of Guidelines Recommendations The guideline recommendations are shown schematically -
ASK SCREEN Test for HIV and STI Practice Steps for Implementation of Guidelines Recommendations The guideline recommendations are shown schematically - Routinely obtain a thorough sexual history from all
More informationAs a result of this training, participants will be able to:
Addressing Sexual Risk with Drug Users and their Partners 1 Day Training This one-day training will build participant knowledge and skills in offering sexual harm reduction options to substance users.
More informationPrevention of and Immunisation against Hepatitis B and C
Prevention of and Immunisation against Hepatitis B and C January 2014 Quality Education for a Healthier Scotland 1 Learning Outcomes Participants will be able to:- Demonstrate an increased knowledge and
More informationHIV/AIDS Think Tank meeting: EMCDDA report. Roland Simon, Klaudia Palczak, EMCDDA Luxembourg, 7 July 2015
HIV/AIDS Think Tank meeting: EMCDDA report Roland Simon, Klaudia Palczak, EMCDDA Luxembourg, 7 July 2015 European Drug Report 2015 Drop o Trends in seizures by substance from 2009 o Drug and related long-term
More informationWhat works: prevention for drug injectors. Holly Hagan Don C. Des Jarlais. Corina Lelutiu-Weinberger
What works: A synthesis of research on HCV prevention for drug injectors Holly Hagan Don C. Des Jarlais Enrique R. Pouget Corina Lelutiu-Weinberger Center for Drug Use and HIV Research NDRI New York, NY
More informationHepatitis B Virus and the Opioid Crisis
Hepatitis B Virus and the Opioid Crisis Alice Asher, RN, Ph.D. Epidemiology and Surveillance Branch Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers
More informationFirst results collected by Argos, DCR in Strasbourg opened in november 2016
Photo Marine Saiah First results collected by Argos, DCR in Strasbourg opened in november 2016 Danièle BADER, Leader of Ithaque Association EMCDDA, DRID Meeting 18-20 september 2017 A crossborder experimentation
More informationSouth African Guidelines for the Safe Use of. Dr. Oscar Radebe
South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &
More informationA review of drug-related deaths in seven Northern European countries
A review of drug-related deaths in seven Northern European countries Tim Millar a & Andy McAuley b a) Division of Psychology & Mental Health, School of Health Sciences, The University of Manchester b)
More informationState of Alabama HIV Surveillance 2014 Annual Report
State of Alabama HIV Surveillance 2014 Annual Report Prepared by: Division of STD Prevention and Control HIV Surveillance Branch Contact Person: Richard P. Rogers, MS, MPH richard.rogers@adph.state.al.us
More informationHIV AIDS and Other Infectious Diseases
HIV AIDS and Other Infectious Diseases Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Chapter 1 - Introduction Despite the availability of a vaccine since
More informationHepatitis C reinfection after sustained virological response in HIV/HCV co-infected patients
Hepatitis C reinfection after sustained virological response in HIV/HCV co-infected patients Fábio Videira Santos, Joana Fragoso, Ana Cipriano, Miguel Araújo Abreu, Olga Vasconcelos, Ana Aboim Horta, Ana
More informationCommunity oriented studies. New perspectives
Community oriented studies. New perspectives Swiss HIV Cohort Study Increased Viral Load Suppression in HIV+ Persons on ART Cohort size: 4624 4852 5045 5279 5556 5830 6121 6418 6526 100 Percent of individuals
More informationJMSCR Vol 3 Issue 10 Page October 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x DOI: http://dx.doi.org/10.18535/jmscr/v3i10.12 Seroprevalance of Hepatitis B and Hepatitis C Virus Infection among HIV Positive Individuals
More informationBeginning in 1994, Vancouver experienced an explosive outbreak of HIV infection
Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection David M. Patrick, * Mark W. Tyndall, Peter G.A. Cornelisse, Kathy Li, Chris H. Sherlock, ** Michael
More informationUC San Diego UC San Diego Previously Published Works
UC San Diego UC San Diego Previously Published Works Title HIV/AIDS risk behaviors and correlates of injection drug use among drug users in Pakistan. Permalink https://escholarship.org/uc/item/7fr8105v
More informationStatistical Table 17: Prevalence of hepatitis C infection among injecting drug users under age 25 in the EU (%) (sample sizes between brackets)
Belgium, French Community 99 992 993 994 995 996 997 998 999 2000 200 / 40.9 (22) 47.4 (38) 3.9 (38) 26.7 (5) SR centres; self-reported test results. > 80% missing data. Belgium, French Community - Charleroi
More informationStrategies of drug users to avoid infection with hepatitis C
With financial support from the Drug Prevention and Information Programme of the European Union Strategies of drug users to avoid infection with hepatitis C Results from five European countries Dr. Heike
More informationEDMA HIV-AIDS TEAM Fact Sheet November 2007
EDMA HIV-AIDS TEAM Fact Sheet November 2007 1. HIV Facts AIDS epidemic update UNAIDS Epidemic Update, November 2007 (1) 760,000 people to be living with HIV in Western and Central Europe in 2007. 31,000
More informationInjecting Drug Users: A Global Problem. Roger Detels, M.D., M.S.
Injecting Drug Users: A Global Problem Roger Detels, M.D., M.S. Global Areas of Drug User- Europe Transmitted HIV North America (U.S., Canada) South America Southeast Asia (Thailand, Myanmar, Vietnam,
More informationWhat is injection drug use?
What is injection drug use? Essential Standards 7.ATOD.1 Understand the health risks associated with alcohol, tobacco, and other drug use. Clarifying Objectives 7.ATOD.1.2 - Explain health risks resulting
More informationPresented at: Annual expert meeting on Drug-related deaths (DRD) and Drug-Related infectious diseases (DRDI), October 2014, EMCDDA, Lisbon
Assessing the gender effect in mortality risk and excess mortality from natural and external causes among heroin and cocaine users in Spain Does being heroin or cocaine user add a differential risk of
More informationThe Relationship Between Age and Cognitive Function in HIV-Infected Men
The Relationship Between Age and Cognitive Function in HIV-Infected en Emily C. Kissel Nicole D. Pukay-artin, B.A. Robert A. Bornstein, Ph.D. Several studies have identified increased age as a risk factor
More informationHIV/AIDS Epi Update Public Health Agency of Canada
8 HIV/AIDS Epi Update Public Health Agency of Canada www.phac-aspc.gc.ca/hast-vsmt/ JULY 2010 HIV/AIDS Among Aboriginal People in Canada At a Glance Aboriginal people remain overrepresented in the HIV/AIDS
More informationMore than 22,000 people have attended the programs of Dianova
DIANOVA ITALY DIANOVA ONLUS WHO WE ARE Dianova in Italy was established in 1984 and later became an Onlus, which in Italian stands for Non-profit Organization of Social Utility. The organization is dedicated
More information